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ABSTRACT  The aim of this study was to determine the effects of forced expression of myocd-A
in the left ventricular (LV) myocardium on cardiac performance in early neonatal piglets. LV
transfection with the gene for homeodomain only protein (hop), an antagonist of myocd-
mediated activities, was also performed. Gene delivery was performed in 6-day-old piglets using
a low-traumatic, catheter-based, video-assisted procedure developed by us for direct intra-
myocardial injections of plasmid DNA into 3-4 target areas of the ventral LV free wall (LVFW). Two
isoforms of porcine myocd were identified, cloned and characterized: the exon 11-lacking myocd-
A and its larger exon 11-containig variant, myocd-B. In neonatal piglets, myocd-A seems to be a
cardio-predominant isoform enriched in the LVFW/septum, whereas the myocd-B isoform is
detected not only in the heart but also in various smooth muscle cell-containing tissues.
Intramyocardial myocd-A gene delivery resulted in forced transgene expression in the target areas
of the LVFW as compared to controls. On day 2 post-delivery, a marked decrease of LV-end systolic
pressure values (an accepted marker for impaired LV function) was observed in myocd-A-
transfected piglets as compared to hop-transfected and control groups. In addition, forced myocd-
A expression in the LVFW caused abnormal ECG. A significant up-regulation of the gene for fetal-
predominant muscle light chain 3F myosin was detected in myocd-A-transfected LVFWs har-
vested on day 2 post-delivery. Extended analysis on day 7 post-delivery revealed a drop decrease
in myocd-A transgene expression in target LVFW regions which was correlated with normaliza-
tion of the LV systolic parameters in experimented piglets.
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 “The heart is the first organ to form and function in the
embryo, and all subsequent events in the life of the organ-
ism depend on the heart’s ability to match its output with the
organism’s demands for oxygen and nutrients”
(Olson, 2004).
Introduction
Myocardin (myocd)  is a cardiac and smooth muscle-selective
co-activator for the ubiquitous transcriptional factor, serum re-
sponse factor (SRF). In the course of embryonic development,
the onset of myocd expression coincides with specification of
early cardiac progenitors in the cardiac crescent. Thereafter,
myocd is expressed throughout the heart and in various subsets
of smooth muscle cells (SMCs) (Creemers et al., 2006a).
Int. J. Dev. Biol. 53: 1457-1467 (2009)
doi: 10.1387/ijdb.072366mt
THE INTERNATIONAL JOURNAL OF
DEVELOPMENTAL
BIOLOGY
www.intjdevbiol.com
*Address correspondence to: Dr. Alexander T. Mikhailov. Developmental Biology Group, Institute of Health Sciences. University of La Coruña. Campus de
Oza, Building "El Fortín", As Xubias s/n. 15006 La Coruña, Spain. Fax: + 34-981-138-714. e-mail: margot@udc.es
Final author-corrected PDF published online: 30th January 2008.
ISSN: Online 1696-3547, Print 0214-6282
© 2008 UBC Press
Printed in Spain
 In Xenopus embryos, expression of a dominant-negative
mutant of myocd (Wang et al., 2001) or inhibition of myocd  activity
by morpholino knockdowns (Small et al., 2005) disrupts cardiac
development and abolishes cardiac marker gene expression.
However, mouse embryos lacking myocd  have a normal heart (Li
Abbreviations used in this paper: ANF, atrial natriuretic factor; EDP, end-
diastolic pressure; ESP, end-systolic pressure; Hop, homeodomain only
protein; LV, left ventricular; LVFW, LV free wall; myocd, myocardin; qRT-
PCR, quantitative real-time RT-PCR; RV, right ventricular; SMC, smooth
muscle cell; SRF, serum response factor; MLC3F, myosin light chain 3F
isoform; CNN1, smooth muscle calponin 1 basic isoform; TAGLN, transgelin
(SM-22); ACTG2, smooth muscle actin gamma 2 isoform; Q, poly(Q)-rich
tract; SAP, SAF-A/B, Acinus and PIAS motif; TAD, transactivation domain;
aa, amino acid residues; EtBr, ethidium bromide.
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et al., 2003) probably due to redundancy of myocd-related factors
(Wang et al., 2002), which are expressed in the developing
mouse, but not in the developing Xenopus heart (Small et al.,
2005). Recently, it was found that myocd is transiently expressed
within the somites of mouse embryos. However, forced myocd
expression in in vitro cultured skeletal myoblasts resulted in
repression of activity of the muscle-specific myogenic factors and
concurrent activation of SMC-specific genes (Long et al., 2007).
It is widely accepted that myocd  is a regulatory factor that plays
pivotal roles in both cardiac and SMC gene expression (recently
reviewed in: Liu and Olson, 2006; Pipes et al., 2006; Parmacek,
2007). In Xenopus embryos, ectopic myocd expression results in
activation of cardiac muscle genes throughout the embryo, in-
cluding spinal cord neurons (Wang et al., 2003), or in animal cap
tissue (Small et al., 2005). In cultured mammalian cells, depend-
ing on the particular cell type in which myocd expression is
induced, different subsets of SRF-dependent SMC and cardiac
muscle genes can be activated (Chen et al., 2002b; Du et al.,
2003; Wang et al., 2003; Yoshida et al., 2003; Hendrix et al., 2005;
Pipes et al., 2005; van Tuyn et al., 2005, 2007a,b; Creemers et al.,
2006a,b; Chow et al., 2007).
However, although myocd is required for cardiac and SMC
gene expression and differentiation, it is not sufficient to cause
other cell types to adopt a cardiac or SMC expression phenotype
(Yoshida et al., 2004). In this regard, myocd can initiate the
expression of cardiac muscle-specified genes in cultured fibro-
blasts, but only in the presence of the co-expressed small ubiquitin-
like modifier, SUMO-1 (Wang et al., 2007). Undifferentiated liver-
derived stem cells acquire a cardiomyocyte phenotype when co-
cultivated in vitro with neonatal cardiomyocytes which, in turn,
results in the de novo activation of cardiac transcriptional factors
including myocd (Muller-Borer et al., 2007). These and other data
(Oh et al., 2004; Callis et al., 2005; Creemers et al., 2006a)
strongly suggest that additional factors are required to promote
myocardin’s role in cardiogenic gene expression.
In addition to its roles in the regulation of cardiac and SMC
differentiation and gene expression, myocd  has also been
implicated in remodeling of the postnatal heart in response to
either physiological or pathological stresses during heart ageing,
cardiomyopathic progression, and at heart failure (see Table 1
and references therein). Physiological and experimental cardiac
hypertrophy is accompanied by marked myocd up-regulation in
ventricular myocardium. In this regard, in vitro forced expression
of myocd in neonatal ventricular cardiomyocytes increases cell
size and expression of molecular markers of cardiac hypertrophy
(Badorff et al., 2005; Xing et al., 2006). Glycogen synthase kinase
3β, suppressor of cardiomyocyte hypertrophy (Michael et al.,
2004), phosphorylates MYOCD, thus antagonizing its pro-hyper-
trophic activity (Badorff et al., 2005).
Taken together, these studies all point to a redeployment of
myocd in processes of postnatal cardiac remodeling (Torrado et
al., 2003; Torrado et al., 2005a; Oka et al., 2007). While some
potential insights into MYOCD/SRF-dependent pathways were
described in cultured neonatal cardiomyocytes, the functional
contributions of myocd signaling to physiological cardiac hyper-
trophy in the neonatal heart in vivo remain unknown.
The primary goal of the present study was to directly assess the
possible roles of MYOCD in the neonatal porcine heart in vivo. To
this end, a new controlled local delivery of myocd-A-expressed
plasmids to left ventricular (LV) myocardium was developed.
Using this low traumatic technique, the effects of transfection-
mediated myocd-A overexpression in the LV myocardium on
cardiac performance and gene expression were monitored in
neonatal pig hearts. As additional experimental treatments, LV
transfection with the gene for homeodomain only protein (hop), an
antagonist of myocd-mediated SRF activities (Kook and Epstein,
2003), was also performed.
Here we show that in vivo forced expression of myocd-A in
ventricular myocardium transiently impairs systolic performance
in neonatal pig hearts. Given that end-stage heart failure is
Fig. 1. Procedure of catheter-based video-assisted intramyocardial
injections of Indian ink suspension into the left ventricular free wall
(LVFW) of 6-day-old piglets. (A) Positions for trans-cutaneous insertion
of the endoscopic cannula (EDC) and fiber-optic device (FOD) into left
chest cavity. The positions were selected to access and visualize the
ventral surface of the heart. (B) Both EDC and FOD are inserted at the
positions indicated. (C,D) Intramyocardial injecting controlled by real-
time video-signals. LV, left ventricle. (E,F,G) Ventral, lateral and dorsal
view of the heart at the 7th day after Indian ink delivery to the ventral
LVFW. Arrows, injection points; RV, right ventricle. (H,I) Histological
sections showing Indian ink infiltration of the myocardium at injection
points. Haematoxylin-eosin staining. Bar, 100 μm.
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accompanied by an increase in myocd expression (see Table 1),
these results demonstrate, for the first time, that myocardial
myocd overexpression might represent a maladaptive response
to cardiac stress.
Results
The use of a newly developed catheter-based device results
in efficient intramyocardial delivery in closed-chest neonatal
piglets
Direct intramyocardial delivery is attractive because specific
myocardial regions can be targeted and high local concentrations
of the transgene can be achieved. However, direct myocardial
gene delivery often requires aggressive surgical interventions
resulting in a low survival rate of experimental animals.
We developed and evaluated the feasibility of a catheter-
based video-assisted surgical approach for direct intramyocardial
gene transfer in closed-chest 6-day-old neonatal piglets (Fig. 1A-
D). For catheter optimization studies, needle length (2-5 mm),
injection volume (50-200 μl/point), and the localization/distribu-
tion of the delivered trackers (Indian ink suspension or β-galac-
tosidase (β-gal) carrying plasmid DNA) were assessed two and
seven days after injections.
The intramyocardial injections were well tolerated in all ani-
mals. Sometimes, injections provoked isolated ventricular ec-
topic beats but no sustained dysrhythmia. In all delivery experi-
ments, piglets became fully ambulatory during the first 30 min
after removal of anesthetics. Histological analysis revealed no
evidence of inflammatory cell infiltration or micro-infarctions in
LVFW regions injected with naked β-gal plasmid DNA at the 7th
day post-delivery. However, injections of the β-gal plasmid DNA
solution supplemented by in vivo-jetPEI transfection reagent (at
N/P=10) did result in signs of inflammation and calcium deposition
in the targeted LVFW regions.
The optimal needle length in these neonatal piglets with a
LVFW thickness of 7.3± 0,3 mm (Torrado et al., 2004) was
determined to be 4 mm and, using this needle length, the optimal
injection volume was determined to be 100 μl/point. Under our
conditions, 3-4 discrete injections (100-150 μl each), spaced 1 cm
apart, in each LVFW resulted in distribution of Indian ink tracker
across ~50% of the ventral LVFW surface (Fig. 1E).
Furthermore, to determine more precise quantitative data
regarding transfection efficiency, myocardial delivery of β-gal
plasmid DNA was performed using the same injection protocol.
Protein extracted from injected and adjacent regions of each
LVFW was assayed for β–gal enzymatic activity. The same or an
even more vast distribution of β-gal enzymatic activity was found
in the corresponding LVFWs as compared to that in myocardium
injected with Indian ink suspension. These results were further
confirmed by reverse transcription-polymerase chain reaction
(RT-PCR) detection of β–gal expression in the injected LVFW
regions (data not shown).
In conclusion, the use of the optimized intramyocardial delivery
device with video-assisted guidance resulted in a relatively effi-
cient delivery of the trackers used to target the regions of the
LVFW with 100% recovery of experimental piglets.
Which porcine myocardin gene to use for delivery?
Previously, we have provided evidence for the existence of two
myocd transcript variants in four cardiac cambers, as well as in
aorta, pulmonary vein, and lung of neonatal piglets (Torrado et al.,
2003). In this work, two porcine myocd variants were cloned,
sequenced and designated, in accordance with our tentative
classification (Torrado et al., 2003), as a myocd-A and its spliced
variant myocd-B, containing a 144-bp insertion due to the pres-
ence of an alternative exon (marked 11 in Fig. 2A and Fig. 4A).
Using RT-PCR, both myocd-A and myocd-B transcripts were
detected in all heart chambers of 6-8-day-old neonatal piglets with
relative myocdA/myocd-B expression ratio (fold expression) of
1:9±2.8 (Fig. 2B, C). Myocd-B was also found to be expressed in
aorta, pulmonary veins, lung and spleen, but its expression was
not detectable in skeletal muscle, liver and kidney. In contrast, in
addition to being expressed in myocardium, myocd-A  mRNA,
was weakly detected only in aorta (Fig. 2C).
To confirm that each of the two myocd transcripts can be
efficiently translated into protein, the corresponding myc/His-
tagged cDNAs were expressed in vitro and the encoded polypep-
tides were detected by SDS-PAGE followed by Western blot with
our lab-derived anti-CT-MYOCD-A (named AB531; see Fig. 4B,
C) or anti-myc antibodies. On blots, both MYOCD-A and MYOCD-
B proteins were detected by each of the antibodies used (Fig. 2D,
E). The experimentally determined molecular weight (MW) value
of myc/His-tagged MYOCD-A (128 kDa) and MYOCD-B (133
kDa) is an ~28 kDa higher than the predicted sequence-derived
Model Cardiac phenotype Phase/Clinical syndrome Myocardin (up/down) Reference 
Young vs  newborn piglets VH due to early postnatal growth Physiological VH transcript (up) Torrado et al., 2003 
Old vs  young adult mice Aging heart  NA transcript (up) Zhang et al., 2004 
Old vs  young adult humans Aging heart NA transcript (up) Zhang et al., 2004 
Adult TAB mice VH due to aortic stenosis No signs of HF transcript (up) Xing et al., 2006 
Calcineirin-transgenic mice VH due to calcineurin overexpression Susceptible to sudden death protein (up) Xing et al., 2006 
SRF-deficient adult mice DCM due to disruption of the SRF gene Early-stage DCM transcript (down) Parlakian et al., 2005 
  End-stage HF transcript (up)  
Dox-injected piglets  DCM due to Dox cardiotoxic effects  End-stage HF transcript (up) Torrado et al., 2003 
F vs  NF human hearts IDCM End-stage HF transcript (up) Torrado et al., 2003 
F vs  NF human hearts IDCM No signs of HF protein (no change) Xing et al., 2006 
 IDCM End-stage HF protein (up)  
MYOCARDIN EXPRESSION LEVELS AT HEART AGING, VENTRICULAR HYPERTROPHY AND HEART FAILURE
TABLE 1
VH, ventricular hypertrophy; NA, not available; TAB, thoracic aortic banding; HF, heart failure; SRF, serum response factor; DCM, dilated cardiomyopathy; IDCM, idiopathic DCM; Dox, doxorubicin;
F, failing; NF, non-failing heart.
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MW of porcine MYOCD-A (~101 kDa) and MYOCD-B (~105 kDa),
respectively.
 To the best of our knowledge differences in apparent versus
deduced MW of MYOCD proteins have not been recognized in
previous studies on mouse myocd (Creemers et al., 2006b; Xing
et al., 2006; Wang et al., 2004, 2007). On the other hand, one can
deduce from published SDS-gel images (see Qiu et al., 2005; Li
et al., 2007) that an apparent  MW of FLAG-tagged mouse
MYOCD seems to be between 120-130 kDa that is similar to the
MW value of myc/His-tagged porcine MYOCD-A (this work). It
seems that the presence of myc/His residues (see Fig. 2D,E) or
FLAG epitopes (see Fig. 3B) in expressed MYOCD proteins
contributes only to a minor extent to analomous slow migration of
the pig MYOCD proteins in SDS-PAGE gels. Of note, the experi-
mentally estimated 5-kDa difference between the myc/His-tagged
128-kDa MYOCD-A and the 133-kDa MYOCD-B closely agreed
with the theoretical 4-kDa size difference between these two
isoforms of porcine MYOCD (i.e., 101 kDa vs 105 kDa).
Furthermore, using AB531-antibodies, a single 145-kDa band
was immuno-decorated on blots of electrophoresed SDS-lysates
from LV but not from skeletal muscle of neonatal piglets (Fig. 2D).
The specificity of this cross-reactivity was confirmed by pre-
absorption of AB531 with the competing peptide, which blocked
immuno-detection of the heart-derived 145-kDa band. Of note,
the fragment 5 of pig myocd-A used as immunogen to generate
AB531 antibodies (see Fig. 4B) is identical for both porcine
myocd-A and myocd-B isoforms. Therefore, it was not surprising
that these antibodies recognized both in vitro  synthesized MYOCD-
A and MYOCD-B proteins (see Fig. 2D). However, we observed
the only one 145-kDa band on piglet LV-derived immunoblots
(see Fig. 2D). Although unproved as yet, we suggest that the band
with an apparent MW of 145-kDa might correspond to an endog-
enous MYOCD-B protein. In this respect, we found that the
myocd-B mRNA is much more abundant than the myocd-A
transcript in the LV (see Fig. 2 B,C) suggesting that under our
experimental conditions presumably MYOCD-B protein might be
detected on LV-derived blots. Differences in an apparent MW
between in vitro expressed MYOCD-B (MW 133-kDa) and heart-
derived protein (MW 145 kDa) may be due to post-translational
modifications of the latter, such as symolation (Wang et al., 2007),
Fig. 2. Analysis of myocd-A and myocd-B expression
in vivo and in vitro. (A) Positions of the oligonucle-
otides 273 and 270 (horizontal arrows) over porcine
myocd-A and myocd-B exon 10 and exon 12 (white
boxes) that have been used in RT-PCR analysis. Spliced
exon 11 in myocd-B is boxed in grey. Bold-faced black
lines indicate 294-bp and 438-bp PCR fragment of the pig
myocd-A and myocd-B, respectively (top part). Nucle-
otide and deduced amino acid sequences of the myocd-
B exon 11 (lower part). (B) Representative
semiquantitative RT-PCR for myocd-A, myocd-B and
RPL19 genes in left and right ventricles (LV, RV) and atria
(LA, RA) of 6-day-old piglets. (C) Expression of myocd-A
and myocd-B in LV-derived tissues and various non-
cardiac tissues/organs of 8-day-old piglets as determined
by semiquantitative RT-PCR. PV, pulmonary vein; SM,
skeletal muscle; L, DNA ladder; Control, non-template
PCR. (D,E) Western blot analysis of in vitro (IVTT) ex-
pressed myc-tagged myocd-A (lane 2, 3) and myocd-B
(lane 4, 5) cDNAs using anti-CT-MYOCD (AB531) and
anti-myc antibodies, respectively. Lane 1 (IVTT control),
non-plasmid DNA negative control. In addition, extracts
prepared from LVFW of 8-day-old neonatal piglets were
probed with anti-CT-MYOCD antibodies (right part of D):
lane 6, LVFW extract (15 μg of total protein); lane 7,
LVFW extract (30 μg of total protein); lane 8, IVTT-
expressed myocd-A protein was loaded together with
LVFW extract (LVFW+MYOCD-A); lane 9, extract from
skeletal muscle (SM, 30 μg of total protein) of 8-day-old
neonatal piglets.
or due to its conformation changes. In this context,
SUMO-modified transcription factors have a ~20
kDa higher apparent MW as compared to unmodi-
fied proteins (Eloranta and Hurst, 2002;
Sapetschnig et al., 2002).
Collectively, the results revealed a differential
expression of myocd-B versus myocd-A genes in
the piglet LV myocardium and a modest but steady
level of myocd-A. In neonatal piglets, the exon 11-
lacking myocd-A seems to be a cardiac-predomi-
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nant isoform enriched in LVFW and septum whereas
the exon 11-containing myocd-B  isoform is ex-
pressed not only in the heart but also in SMC-
containing tissues such as aorta, pulmonary veins,
lung and spleen (see Fig. 2 A-C). Of note, forced
expression of similar (see Fig. 4A) human myocd-A
and myocd-B isoforms in myocardial scar fibroblasts
didn’t reveal significant differences in their
transactivating capacity, making the biological rel-
evance of myocd-B exon 11 uncertain (Tuyn et al.,
2007b). Additionally, we reasoned that since the
baseline levels of myocd-A expression are low in the
piglet myocardium, the consequences of forced
myocd-A expression in the LVFW could be more
palpable than in case of myocd-B delivery. Given
also that comparison of the effects and quantitative
measurements of the delivered myocd variants could
significantly interfere with endogenous myocd  tran-
scripts/proteins, for gene delivery experiments we
used the myocd-A-carrying plasmid.
Intramyocardial delivery of myocardin-A results
in transiently impaired systolic performance
Using the optimal delivery protocol developed in
the first part of the work, naked plasmids encoding
myocd-A gene, hop gene or vector itself were in-
jected directly into target sites of the LVFW of 6-day-
old neonatal piglets. Two days after delivery, nine
regions of each injected LVFW (Fig. 3A) were as-
sayed individually by Western blot with anti-FLAG-
antibody (Fig. 3B) and RT-PCR (Fig. 3C,D). To en-
sure the specificity of RT-PCR for delivered cDNAs,
we used RT-PCR with discriminating primer sets. In
all RT-PCR experiments, we observed highly specific
amplification of only the template specific for the
discriminating downstream primer complementary to
the FLAG-tagged myocd-A (Fig. 3C, D) or hop se-
quence (data will be described elsewhere).
All myocd-A-transfected LVFWs (n=10) harvested
on day 2 post-delivery demonstrated transgene ex-
pression detectable by RT-PCR. The relatively high
ectopic expression of the FLAG-myocd-A was re-
stricted almost exclusively to segments 3, 5, and 6
that included the injection sites. FLAG-myocd-A trans-
gene expression was not found in other tissue seg-
ments except in the two LWFWs, which also revealed
transgene expression in region 2 and 4 (Fig. 3C). The
results of non-RT control PCR runs demonstrated
that the FLAG-myocd-A PCR product was amplified
from LV cDNA, but not from plasmid DNA (see Fig.
3D). On average, the estimated extent of FLAG-
myocd-A expression was 40% of the overall area of
the ventral LVFW. Target delivery regions of LVFWs
(i.e., region 3, 5, and 6) injected with hop or empty
vector were consistently negative for FLAG-myocd-A
transgene expression (data not shown).
The myocd-A/myocd-B mRNA ratio in FLAG-
myocd-A-delivered LVFW regions was significantly
affected as compared to that in myocardium of PBS-
Fig. 3. Representative analysis of FLAG-tagged myocd-A expression in the  left
ventricular free wall (LVFW) myocardium 48 h after gene delivery (8-day-old
piglets). (A) myocd-A transfected LVFW (arrows, injection positions) was dissected
into nine fragments (1-9). RV, right ventricle; RA and LA, right and left atrium,
respectively. (B) Western blot detection of FLAG-tagged MYOCD-A protein in dis-
sected target (3, 5, 6) and adjacent (4, 8) regions of myocd-A transfected LVFW. (C)
Semiquantitative RT-PCR analysis of FLAG-tagged myocd-A transcript levels in nine
LVFW segments (after normalization of the cDNA templates to RPL19 expression). ND,
non-delivered myocardium. (D) Control of plasmid DNA contamination in RNA prepa-
rations used in downstream RT-PCR assays (see C,E). Total RNA was isolated from the
target regions 5 and 6 of myocd-A transfected LVFW (see A). Four μg of each RNA
preparation were reverse transcribed (RT) in 20 μl reaction mix. One μl of each RT
reaction (+RT) and 1 μg of each RNA (-RT) were subsequently used in a standard PCR
reaction for the amplification of the FLAG-tagged  myocd-A message. Equal volumes
of each PCR reaction were assessed on a 2% agarose gel and stained with EtBr. L,
GeneRuler DNA ladder mix (Fermentas). (E) Semiquantitative RT-PCR analysis of total
RNAs isolated from the indicated zones (Z5, Z6) of LVFWs injected with PBS (piglet
#171), empty vector (piglet #157) or FLAG-tagged myocd-A (piglet #166 and #168)
plasmids. Upper part, recombinant FLAG-myocd-A transcript levels. Middle part,
endogenous/recombinant  myocd-A and endogeneous myocd-B transcript levels.
Lower part, RPL19 transcript levels.
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Fig. 4. Alternative splicing yields different myocd  transcripts with similar
C-termini coded by exons 13 and 14. (A) Schematic diagrams of three
different  myocd isoforms (marked respectively in red, blue and green)
detected in cardiac and SMC-containing tissues. Myocd, gene name approved
by HUGO Gene Nomenclature Committee. Transcript symbols are indicated in
accordance with original definitions. 1-14, exons (alternative exon 2A and 11
are boxed in white). In each myocd isoform, the transactivation domain is coded
by similar exons 13 and 14. The exon 11-lacking myocd A (blue) and exon 11-
containing myocd-B (red) have similar N-terminal peptide sequences. Green, N-
terminus truncated myocd isoform. ATG and TC, translation initiation and
termination codon, respectively. aa, amino acid residues. N/A, not available. (B)
Five fragments (F1-5 marked by bold-faced black lines) covering the major part
of the sequence of porcine MYOCD-A were cloned, expressed and purified as
described in Materials and Methods. The C-terminal (CT) fragment 5 of porcine
MYOCD-A (aa 731-873) was used, as immunogen, to generate AB531 antibod-
ies. Q, poly(Q)-rich tract. SAP, SAF-A/B, Acinus and PIAS motif. TAD,
transactivation domain. (C) Purified fragment products (F1-5) were separated
by SDS-PAGE followed by Coomassie staining of gels (left) or Western blot
(WB) with anti-FLAG (center) and AB531 antibodies (right). Anti-FLAG antibod-
ies detect all fragments due to presence of the FLAG epitopes in each
expressed protein. AB531 antibodies recognize only the CT fragment 5 used
for immunization; no cross-reactively was observed with other MYOCD-A-
derived fragments. LMW, Amersham low molecular weight calibration kit.
and vector-delivered (Fig. 3E) or age-matched
(Fig. 2B,C) piglets. In the target regions, deliv-
ered FLAG-myocd-A caused an increase of the
myocd-A transcript content in direct proportion
to the transgene expression level. The amount
of the endogenous myocd-B  RNA did not change
appreciably in myocd-A-delivered regions (Fig.
3E). Of note, intramyocardial delivery of the
vector itself did not influence endogenous myocd-
A/myocd-B mRNA levels in the target regions of
LVFWs. Histological examination did not reveal
inflammation or fibrosis in the LVFW target re-
gions from myocd-A- delivered piglets (data not
shown).
Ventricular systolic function was clearly al-
tered in myocd-A-delivered piglets as compared
with that in animals intramyocardially injected
with hop-plasmid or the vector itself. Particularly,
intramyocardial injections of myocd-A resulted
in a marked decrease of LVESP, an accepted
marker for impaired LV function. In addition,
forced myocd-A expression in the LVFW caused
abnormal ECG including T-wave inversion (Table
2). In hop-delivered and control groups, there
was no change in ECG parameters from gene
delivery to final studies, nor were there differ-
ences in LVESP values between these groups.
In all animals, LVEDP (a marker for LV com-
pliance) values were the same regardless of
whether myocd-A or other plasmids were deliv-
ered into myocardium. In myocd-A delivered
hearts, there was no difference in the heart mass
as assessed by the ratios of heart/body weight
compared with control piglets (Table 2).
To examine the duration of expression from
the delivered myocd-A naked DNA, we have
analyzed by RT-PCR the level of FLAG-myocd-
A mRNA in hearts (n=5) harvested after 7 days
after gene delivery. On day 7, the transgene expression
level in the LV target regions was, on average, 3-fold less
than that on day 2. The systolic parameters were not altered
in this animal group as compared to age-matched controls
(i.e., 13-day-old piglets; n=4) transfected with empty vector
(data not shown). These experiments show the transient
character of myocd-A transgene expression in the heart and
strongly suggest that only a highly forced myocd-A expres-
sion might have a functional consequences on LV systolic
performance.
Considering the well-established involvement of myocd
in regulating both cardiac and SMC gene expression, we
studied in myocd-A-delivered hearts the endogenous ex-
pression of a set of the genes previously shown to be bona
fide myocd targets. Expression of selected cardiac and
SMC marker genes was assessed by qRT-PCR in FLAG-
myocd-A- (n=5) versus vector-delivered (n=4) piglets two
days after transfection (Table 3; Fig. 5). These gene expres-
sion studies were performed using myocardial samples
derived from two target region 5 and 6 (see Fig. 3A) of each
LVFW transfected with myocd-A (5 animals) or empty vector
myocd isoform:
Exon 11-containing ("large")
Species Symbol Acc. No. Protein, aa Reference
Pig myocd-B N/A 981 this work
Human myocd-B AY764180 986 van Tuyn et al ., 2005
Mouse myocd-A NM_145136; AY303755 983 Wang et al ., 2001; Ueyama et al., 2003
Exon 11-lacking ("small")
Species Symbol Acc. No. Protein, aa Reference
Pig myocd-A NM_213745 933 Torrado et al ., 2003
Human myocd-A NM_153604 938 Wang et al ., 2001; van Tuyn et al ., 2005
Mouse myocd-B NM_146386 935 Wang et al ., 2001; Creemers et al ., 2006b
Rat myocd NM_182667 938 Chen et al ., 2002
Exon 11-lacking with exon 2A insertion
Species Symbol Acc. No. Protein, aa Reference
Mouse myocd-856 N/A 856 Creemers et al ., 2006b
1 2 3 4 5 6 7 8 9 10 12 1413
TCATG
1 2 3 4 5 6 7 8 9 10 12 1413
TC
2A
ATG
1 2 3 4 5 6 7 8 9 10 11 12 1413
TCATG
WB: anti-FLAG WB: AB531SDS-PAGE:Coomassie
F1 1F2 F3 F4 F5LMW LMW LMW
97
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C
933TAD
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Coded by exon:
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A
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Parameter  myocd-A  hop 
 β-gal  Vector itself 
Number of animals 10 6 6 4 
Heart to body weight ratio, x1000 6.5±0.3 6.9±0.3 7.4±0.4 6.5±0.2 
Heart rate (beats/min) 163±35 161±40 174±31 140±16 
LV end-systolic pressure (mm Hg) 37.2±3.2* 62.2±4.2 61.8±3.1 61.0±3.3 
LV end-diastolic pressure (mm Hg) 4.6±1.4  5.6±1.4 4.3±1.3 5.5±1.2 
T-wave ischemic changes, % 20 0 0 0 
CARDIAC PARAMETERS OF NEONATAL PIGLETS
INTRAMYOCARDIALLY INJECTED WITH MYOCD-A, HOP, β-GAL,
AND PLACEBO PLASMIDS ON DAY 2 POST-DELIVERY
* p< 0.05
TABLE 2
Fig. 5. Representative qRT-PCR analysis of mlc3f (A) and tagln (B)
expression levels in myocd-A versus vector-transfected left ven-
tricular (LV) myocardium two days after delivery. For each gene,
mRNA levels (normalized to (C) the internal standard rpl19) were mea-
sured in six samples, each derived from the target region 5 (see Fig. 3A)
of three myocd-A- (blue plots) and three empty vector-injected (red plots)
LVFWs. CT , cycle threshold; ΔCT , differences in threshold cycles for
target and reference. Calculated fold-change in mlc3f and tagln expres-
sion levels is shown. FT, fluorescence threshold. NTC (green), non
template control.
(4 animals). In total, 10 FLAG-myocd-A- and 8 vector-delivered
samples were processed. The gene for myosin light chain 3F
(mlc3f) displayed the most remarkable, over 8-fold up-regulation
in response to intramyocardial myocd-A delivery (Fig. 5A; Table
3). Of note, we didn’t detect expression of the spliced mlc1f
isoform in the neonatal myocardium of 8-day-old control and
myocd-A transfected piglets. Among the studied SMC marker
genes, only trangelin/SM-22 (tagln) was markedly and statisti-
cally significantly stimulated in response to FLAG-myocd-A (Fig.
5B, Table 3). The expression levels of the gene for atrial natri-
uretic factor (anf), smooth muscle calponin 1 (cnn1) and smooth
muscle actin gamma 2 (actg2) were also up-regulated in the
myocd-A-delivered LVFW regions as compared to those injected
with the vector itself, but the differences were not statistically
significant.
Collectively, the results indicate that under our experimental
conditions myocd-A-delivered hearts shown signs of transiently
impaired systolic function that is associated with marked activa-
tion of mcl3f and tagln expression in target LVFW regions on day
2 post-delivery.
Discussion
The recent discovery of MYOCD that modulates the activities
of SRF in cardiac and SMC tissues (Wang et al., 2001) has led to
intensive investigation into the role that MYOCD can play in heart
development and disease and has revealed new combinatory
pathways by which MYOCD can regulate cardiac gene expres-
TABLE 3
Gene Acc. No. Fold change 
mean ± SEM 
  myocd  target / reference 
mlc3f DQ629159 8.1±1.5 * cardiac / Creemers et al., 2006b 
anf NM_214260 1.2±0.2   cardiac / Xing et al., 2006 
cnn1 NM_213878 1.3±0.2   SMC / Chen et al., 2002b 
tagln AK234135 2.9±0.3 * SMC / Yoshida et al., 2003 
actg2 AK240464 1.4±0.2   SMC / Pipes et al., 2005 
RESPONSES OF CARDIAC AND SMC MARKER GENES TO
FORCED MYOCD-A EXPRESSION IN LVFW TARGET REGIONS
ON DAY 2 POST-DELIVERY
qRT-PCR analysis of mRNA levels of target genes (normalized to the internal standard rpl19) in
FLAG-myocd-A delivered LVFW regions (sample size=10, see text). Fold change as compared
to LVFW regions injected with empty vector. References – bibliographic information used for our
selection of the genes as the direct myocd  targets. mlc3f, myosin light chain 3f isoform; anf, atrial
natriuretic factor gene; cnn1, smooth muscle calponin 1 basic isoform; tagln, transgelin (SM-22);
actg2, smooth muscle actin gamma 2 isoform. * p< 0.05.
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sion (reviewed in: Liu and Olson, 2006; Pipes et al., 2006;
Parmacek, 2007). However, consequences of MYOCD up-regu-
lation during physiological and pathological LV remodeling in the
postnatal heart in vivo (see Table 1) have not yet been high-
lighted. In this study, we present the results of the first step of our
approach to determining whether MYOCD up-regulation in the LV
of neonatal piglets might have functionally significant conse-
quences.
As previously reported, mouse (Wang et al., 2003), human (Du
et al., 2003; van Tuyn et al., 2005) and pig (Torrado et al., 2003)
myocd gene can undergo alternative splicing in cardiac and SMC-
containing tissues. Our in silico analysis (Fig. 4A) of the myocd
gene transcript variants identified in human, pig, rat and mouse
cardiac and SMC-containing tissues shows that: (1) differential
splicing does give rise to, at least, three different myocd  tran-
scripts: myocd-A, myocd-B, and N-terminus truncated isoform,
(2) both myocd-A (i.e., the exon 11-lacking isoform) and myocd-
B (i.e., the exon 11-containing isoform) initiate translation at the
ATG codon located in exon 1 producing a MYOCD-A “small” (933-
938 aa) and MYOCD-B “large” (981-986 aa) protein, respectively,
and (3) alternative splicing of exon 2 to exon 2a, introduces a stop
codon in exon 1 so that translation is initiated from the additional
ATG codon located in exon 4 generating the 856 aa protein
variant. Excepting this N-terminus truncated isoform, all myocd-
A/B alternative variants contain the domains required for interac-
tions with SRF and myocyte-specific enhancer factor 2 (MEF2),
as well as, the transactivation domain. The N-terminus truncated
isoform lacks the sequence required for interaction with MEF2
(Creemers et al., 2006b).
In this work, two forms of the porcine myocd were identified,
cloned and characterized (see Fig. 2 and Fig. 4A): myocd-A and
its larger splice variant, myocd B. Both isoforms of porcine myocd
are expressed in cardiac chambers of the neonatal pig heart with
much lower levels of the myocd-A transcript as compared to those
of the myocd-B. These results are consistent with the data on
expression patterns of the similar myocd-A and myocd-B tran-
scripts in human heart (van Tuyn et al., 2005) but differ from those
in mouse. In mouse, the myocd-B isoform (encoded a 935-aa
protein) was detected by RT-PCR predominantly in the heart,
whereas the N-terminus truncated myocd  isoform (encoded a
856-aa protein), in aorta (Creemers et al., 2006b). In this light, in
neonatal piglets the myocd-A “small” isoform enriched in LV and
ventricular septum seems to be a cardiac-predominant isoform,
whereas the myocd-B  “large” variant is expressed at comparable
levels not only in the heart but also in aorta and pulmonary veins
(see Fig. 2 B,C).
Comparison of the human isoforms of myocd  (that are similar
to porcine myocd-A and myocd-B; see Fig. 4A) failed to detect
differences in their transactivating capacity (van Tuyn et al., 2005,
2007b). The present study demonstrates that one-time direct
intra-myocardial administration of naked plasmid encoding the
porcine myocd-A results in the sustained expression of the
delivered gene in the target regions of the piglet LVFW on day 2
post- delivery. In turn, this forced myocd-A expression in the LV
myocardium results in impaired systolic function. Notably, LVFW
delivery of the hop gene that can diminish the cooperativity
between MYOCD and SRF (Chen et al., 2002a; Shin et al., 2002)
or empty vector did not result in altered ventricular performance.
FLAG-tagged myocd-A expression was significantly downregu-
lated in target LV regions 7 days after delivery that coincided with
full recovery of LV systolic performance in experimented piglets.
 In fact, we demonstrated that the injection of naked myocd-A
DNA, whose high transgene expression could be detected within
first several days post-delivery, was enough to trigger a transient
LV systolic dysfunction. How can this effect be explained? Im-
paired LV performance might have been most easily rationalized
by forced expression of the myocd-A isoform, the level of which
is much lower in normal piglet (this work) and human (van Tuyn
et al., 2005) LV myocardium in comparison to levels of the spliced
myocd-B isoform. Thus, one possibility is that selectively altered
expression of the myocd-A over baseline may be non-physiologi-
cal for rapid postnatal remodeling of the LV myocardium. In this
sense, we detected a significant mcl3f up-regulation in neonatal
porcine myocardium in response to myocd-A delivery (see Table
3, Fig. 5A). Although mcl3f  expression was previously thought to
be restricted to fast skeletal muscles, later the gene was found to
be also expressed in developing mouse heart. Its expression is
down-regulated after birth and no traces of the MLC3F protein
was detected in adult mouse heart (Kelly et al., 1995; 1998;
McGrew et al., 1996). It is formally possible that overexpression
of the fetal-predominant MLC3F fast myosin isoform in neonatal
LV-myocardium in response to myocd-A delivery might interfere
with other MLC proteins altering, in turn, the contractile perfor-
mance of growing piglet myocardium. We cannot also discount
the possibility that in porcine neonatal myocardium the myocd-A/
myocd-B ratio might act as a “dimmer switch” to fine-tune expres-
sion levels of a set of SRF-dependent genes. In this sense, the
shifting of the myocd-A/myocd-B ratio in myocd-A-delivered LVFW
regions in favor of myocd-A (see Fig. 3D) may have maladaptive
consequences for LV functioning.
An additional influence that might act to impair systolic perfor-
mance is that under our experimental conditions the target tissue
to be transfected by the myocd-A DNA was not only proper LV
myocardium but also its outer-most layer including the coronary
arteriolar network. In this context, MYOCD overexpression in
human vascular SMCs induced a hypercontractile phenotype by
enhancing the expression of SRF/MYOCD-dependent contractile
genes (Chow et al., 2007). In this work, we detected the up-
regulation of several SMC-specific contractile filament genes
(especially, tagln/SM22) in response to myocd-A delivery (see
Table 3, Fig. 5B). Therefore, it is not unreasonable to speculate
that a possible “contaminant” myocd-A overexpression in both
superficial and intramyocardial arteriolar network could promote
a hypercontractile SMC phenotype in LV microvasculature, which,
in turn, might result in disturbance of LV myocardium perfusion
and contractile performance. At present, we have no direct
experimental results supporting this hypothesis, and only further
work will clarify whether such mechanism is really operating.
Forced myocd expression in cultured neonatal ventricular
cardiomyocytes resulted in cell hypertrophy and induction of
endogenous anf  transcription (Badorff et al., 2005; Xing et al.,
2006). In this work, neither histological signs of ectopic
cardiomyocyte hypertrophy nor appreciable anf gene up-regula-
tion were observed in target LVFW regions two days after myocd-
A gene delivery. Most probably, this is because LV-cardiomyo-
cytes in 6-8-day-old piglets undergo intensive physiological hy-
pertrophy that is accompanied by a relatively high ventricular anf
expression (M. Torrado and A.T. Mikhailov, unpublished data).
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Such a hypertrophic state of targeting LV-cardiomyocytes may
mask or even impose a pro-hypertrophic effect of forced myocd
expression in vivo. Alternately, the myocd-mediated hypertrophic
effect, which has been identified in an in vitro model system, may
be difficult to mimic in in vivo settings because the response of
targeting LV-cardiomyocytes to elevated myocd expression in vivo
could be modified by their interactions with adjacent non-trans-
fected working myocytes as well as with other cell types (i.e.,
impulse-conducting cardiomyocytes, endothelial cells, and car-
diac fibroblasts) compounding neonatal LV-tissue.
In summary, our data revealed that under apparently normal
hypertrophic growth the outcome of the response of the LV, as a
heterotypic cell system, to elevated myocd-A expression might be
maladaptive. More broadly, this observation is consistent with the
suggestion (Pipes et al., 2006) that myocd overexpression might
represent a maladaptive response to pathological remodeling of
the heart.
Concluding remarks
This study is the first to show possible functional consequences
of forced MYOCD-A production in the LVFW resulting from direct
intra-myocardial gene transfer in vivo. Despite the efficiency of our
gene delivery technique, it is unrealistic to expect a 100% myocd-
A-transfection of every cell in LVFW. Nevertheless, ventricular
performance was affected in experimental piglets although, on
average, no more than 40% of the LVFW was efficiently trans-
fected by myocd-A. The results show that even local changes in
MYOCD dosage (and, consequently, in MYOCD-A/MYOCD-B
ratio) may modulate the responsiveness of LV-myocardium to
overload during early postnatal development. Observed transient
deterioration in ventricular performance of the neonatal heart in
response to a local myocd-A overexpression in the LV myocardium
suggests that cessation of ventricular myocd-A expression at
early-stage cardiomyopathy might represent a safety feature from
a therapeutic point of view. Although this is an encouraging idea,
it remains to be determined whether myocd-A forced expression in
the LV may be a maladaptive background upon stress, resulting in
pathological LV remodeling. Our preliminary results indicate that in
neonatal piglets LV myocd-A transfection followed by adriamycin-
induced cardiomyopathy resulted in a significantly lower survival
rate of the transfected animals compared to controls.
Materials and Methods
Gene cloning and in vitro expression
The full-length porcine myocd-A (GenBank accession no. NM_213745)
and myocd-B (this work, see Fig. 2A) were amplified from piglet LV oligo-
dT primed cDNA, cloned into T7 promoter-containing vector pcDNA3.1/
myc-His B (Invitrogen), verified by sequencing and expressed in vitro using
TnT T7 Quick Coupled in vitro Transcription/Translation (IVTT) System
(Promega) in the presence or absence of [35S]-labeled methionine as
described (Torrado et al., 2005a). The corresponding protein products
were purified on Sephadex G-50 columns (Amersham Bioscience) and
used in downstream SDS-PAGE and Western-blot experiments.
Plasmid DNA
The following expression plasmids in p3XFLAG-CMV-14 vector (Sigma)
driven by a human cytomegalovirus (CMV) promoter/enhancer were used:
(1) myocd-A plasmid, encoding a FLAG-tagged full-length porcine myocd-
A gene; (2) hop plasmid, encoding a FLAG-tagged full-length porcine hop
(GenBank accession no. NM_213792), (3) reporter plasmid encoding the
bacterial gene for β–galactosidase (β-gal), and (4) vector plasmid only
(control empty vector). All the DNA constructs were verified by sequencing.
Plasmids grown in XL1-Blue Supercompetent E. coli cells (Stratagene)
were purified by using a PureLink HiPure plasmid filter purification kit
(Invitrogen) according to the manufacturer’s protocol. Plasmids were
formulated at a final DNA concentration of 1 mg/ml in sterile isotonic saline
(PBS).
Animals and experimental procedures
Animal care and handling conformed to the guidelines of the European
Commission Directive 86/609/EEC on the protection of animals used for
experimental and other scientific purposes and were approved by the
Institutional Ethics Committee of the University of La Coruña. Litters of
Large White domestic pigs were maintained in the Nütinger automatic
nursery system, randomized in five groups and assigned to receive
intramyocardial injections of: (1) myocd-A plasmid DNA (n=16), (2) hop-
plasmid DNA (n=6), (3) β–gal-plasmid DNA (n=6), (4) vector alone plasmid
(n=8), and (5) 2% Indian ink (Winsor & Newton, UK) suspension in PBS
(n=6). Neonatal 6-day-old piglets were sedated, intubated, and anesthe-
tized. While under anesthesia and mechanical ventilatory support, ECG
was monitored followed by trans-costotranversal inserting a fiber-optic
catheter (Cardio-Optics Inc.) and endoscopic tubular (3 mm) cannula into
left chest cavity. The pericardium was opened, and the catheter and
cannula were moved to access and visualize the ventral surface of the left
ventricle free wall (LVFW). Then, the endoscopic needle was introduced
into the cannula, and intramyocardial injections were performed (as de-
tailed in the body text) in the ventro-lateral area of the LVFW. To minimize
leakage of injectate from the puncture site, each injection was performed
slowly under direct visualization. Intra-operative monitoring of cardio-
vascular parameters (blood pressure, pulse rate, body temperature) was
performed during the procedure. On the 2nd and 7th day after gene transfer,
ECG was monitored in closed-chest piglets followed by measurements of
ventricular end-systolic (LV/RV-ESP) and end-diastolic pressure (LV/RV-
EDP) in open-chest piglets using a Dräger UM3.1 pressure transducer and
a recording device (Drägerwerk AG, Germany) as described (Torrado et al.,
2006). Then animals were euthanized and the hearts were rapidly excised,
weighed, and photographed. All these procedures were conducted by two
investigators blinded to the experimental design. The ventral LVFW of each
heart was sectioned into 9 regions (~ 1x1 cm each; see Fig. 3) which were
then assayed individually for RNA and protein isolation, and tissue fixation
(Torrado et al., 2004; Torrado et al., 2005b; Torrado et al., 2006).
Semiquantitative RT-PCR
Total RNA was extracted by RNAeasy-Mini Kit (Qiagen) according to
the manufacturer’s protocol, subjected to on column digestion of DNA with
RNase-free DNase (Qiagen), and reverse transcribed using the SuperScript
III (Invitrogen) and oligo-dT primers. Semiquantitative RT-PCR was per-
formed as described previously (Torrado et al., 2003; Torrado et al., 2004).
All PCR reactions included primers for the candidate (myocd-A or myocd-
B) and control (ribosomal protein L19 - RPL19) genes. Porcine myocd-A
and myocd-B  were amplified with the oligonucleotides 273 and 270
generating 294-bp myocd-A and 438-bp myocd-B PCR-products (see Fig.
2A,B). Discriminating primer set for the specific amplification of delivered
FLAG-tagged myocd-A was 279 and 239 (derived from the FLAG vector
sequence) for a 577-bp PCR product. The porcine RPL19 (accession no:
BI181894) was used to design oligonucleotides 36 and 65 for a 480-bp PCR
product. Reactions, including NRT (non-RT control) and NTC (no template
control), were performed at least in triplicate. PCR products were visualized
on 2% agarose gels by ethidium bromide (EtBr) staining and band intensity
was estimated by densitometry (VersaDoc 1000) and Quantity One soft-
ware (Bio-Rad).
Quantitative real-time RT-PCR (qRT-PCR)
qRT-PCR was performed using SYBR Green Master Mix (Bio-Rad) on
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Bio-Rad IQ5 instrument as described (Torrado et al., 2006) with the addition
of primer pairs targeting transcripts encoding (see Table 3) the porcine
mlc3f (primers 292 and 293), anf (primers 266 and 267), cnn1 (primers 295
and 296), tagln/SM-22 (primers 297 and 298), and actg2 (primers 301 and
302). The primer pairs were located in different exons to rule out genomic
DNA amplification. Each primer pair used yielded a single peak of dissocia-
tion on the melting curve and a single band with the expected size on
agarose gel. Identity of the PCR products was confirmed by sequencing.
Non-template and non-RT RNA template reactions were used as negative
controls. Results were normalized against RPL19 expression (oligonucle-
otides 64 and 206). The efficiency of target and reference amplification was
tested to be approximately equal. Primer sequences and additional details
on RT-PCR/qRT-PCR are available upon request.
β-gal enzyme activity assay
β-gal enzyme activity was measured in LVFW extracts using a high
sensitivity β- galactosidase Assay Kit (Stratagene) with standards supplied
by the manufacturer at pH 8.0 to minimize non-specific staining. Enzyme
activity values were normalized to total protein concentration determined
using the Bio-Rad DC Protein Assay.
Antibody production
The C-terminal part (amino acid residues 731-873; CT-MYOCD) of
porcine MYOCD-A (GenBank accession no: NP_998910) was cloned into
pCAL-n-FLAG vector (Stratagene) and expressed in Rosetta-gami B(DE3)
(Novagen). Recombinant CT-MYOCD-A (fused to the 5-kDa tag, which
included the calmodulin-binding peptide (CBP) and FLAG peptide) was
purified from bacterial lysates using calmodulin-affinity resin (Stratagene)
and used as immunogen. Polyclonal antibodies against porcine CT-
MYOCD-A were raised in rabbits by Davids Biotechnologie (Regenburg,
Germany). Obtained anti-CT-MYOCD-A antibodies (marked by us as
AB531) were shown to be specific for recombinant porcine MYOCD-A and
MYOCD-B by Western blot with competing peptide. Five fragments cover-
ing the major part of the sequence of porcine myocd-A were cloned and
expressed as just described, and resulting purified products were probed
by Western blot with anti-FLAG (Sigma) and our lab-derived AB531
antibodies (Fig. 4B,C). Anti-FLAG antibodies detected each of the ex-
pressed myocd-A fragments, whereas AB531 antibodies recognized only
the CT-MYOCD-A (i.e., the immunogen); no cross-reactivity was observed
with other MYOCD-A-derived fragments. These results indicated that
AB531 antibodies detect only the TAD-containing CT-fragment, a region
that is similar for all the myocd isoforms identified to date in cardiac and
SMC-containing tissues (see Fig. 4A).
SDS-PAGE and Western blotting
LVFW tissue samples were homogenized and solubilized in standard 2x
Laemmli sample buffer as previously described (Torrado et al., 2006).
Extracted proteins were subjected to SDS-PAGE (Mini-Protean-III, Bio-
Rad), stained with Coomassie or blotted onto PVDF membranes (Hybond-
P, Amersham Bioscience), and probed with rabbit polyclonal antibodies
against porcine MYOCD or mouse monoclonal anti-myc or anti-FLAG
antibodies (Sigma). Molecular weight (MW) standards (MARK-12 and
SeeBlue Plus2 from Invitrogen, and high and low MW calibration kits from
Amersham Biosciences) were included on each gel. Equivalence of protein
loading was confirmed by Amido-Black staining of blots before (blot-
replicas) and after immunodetection. Blocking, washing, incubation with
diluted primary and secondary HRP-conjugated antibodies (Sigma), and
visualization of immunodecorated bands by the Super-Signal West Pico
chemiluminescent substrate (Pierce Biotechnology) was carried out as
previously described (Torrado et al., 2005a; Torrado et al., 2006). IVTT-
synthesized myc-tagged pig MYOCD-A or MYOCD-B was included as a
positive control for anti-CT-MYOCD-A antibodies. Substitution of the
primary antibodies with anti-CT-MYOCD-A antibodies neutralized by the
competing peptide was included in negative controls.
Histology
LVFW tissue samples were fixed in 4% formalin in PBS and embedded
in paraplast (Sigma). Serial transverse 5 μm-sections were subjected to
haematoxylin-eosin, Masson’s trichrome and von Kossa staining (Bancroft
and Stevens, 1996) and examined under a “Nikon Eclipse 600” micro-
scope by an experienced technician blinded to the gene-delivery experi-
ments.
Statistics
Results are expressed as mean± SEM. Statistical significance was
evaluated by Student’s t  test. Statistical analyses were performed with
the SPSS 13 software. A value of p< 0.05 was considered statistically
significant.
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